Rory Nealon Chief Financial Officer and Chief Operating Officer (CFO & COO), Chief Financial Officer and Chief Operating Officer (CFO & COO). Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. He has had a diverse and distinguished legal career, evenly split between private practice and public service. Dr Helen Phillips joined Amryt Pharma in December 2016. While there, he had clinical development, medical affairs and pharmacovigilance responsibility for the global approval and launch of a new treatment, Lojuxta®▼(lomitapide), for the serious and rare genetic disease, Homozygous Familial Hypercholesterolemia. He was Chairman, Chief Executive Officer and majority shareholder of the Tosara Group who owned, manufactured and marketed the successful international brand Sudocrem. View Joseph Wiley’s professional profile on Relationship Science, the database of decision makers. Dec 23, 2020 (GLOBE NEWSWIRE via COMTEX) -- Dr. Munoz, M.D., Ph.D. is an entrepreneur and independent management consultant in the pharmaceutical and biotechnology industry, and has over 30 years of experience in the industry at the executive level. In a statement, Joe Wiley, Amryt Pharma’s chief executive, said: “We are very excited to report NICE’s approval which will now give all England and Wales based patients suffering from … Joe Wiley, CEO of Amryt Pharma, commented: "Receiving an orphan drug designation from the FDA for our gene-therapy candidate, AP103, is a significant development for patients … George Hampton Jr Non-executive Director. Prior to Aegerion, he was at Bristol-Myers Squibb, where he led a large US medical affairs team within the cardiovascular and metabolics area. He has a Masters of Business Administration from INSEAD and is also a Member of the Royal College of Physicians in Ireland. Dr. Wiley trained in general medicine at Trinity College Dublin, specialising in neurology. Dr Joe Wiley, CEO of Amryt Pharma, commented today: “We are very excited to report NICE’s approval of Myalepta® which will now give all England and Wales based patients suffering from … She joined Amryt in June 2019. Amryt Pharma PLC (LON:AMYT) (NASDAQ:AMYT) noted that support groups for people suffering from eating disorder leptin deficiency said they were 'ecstatic' after its treatment for the condition, Myalepta, … The person making this notification on behalf of Amryt is Rory Nealon, CFO/COO and Company Secretary. Dr Joe Wiley, CEO of Amryt Pharma, commented today: "We are very pleased that the Ministry of Health in the Kingdom of Saudi Arabia has approved the reimbursement of Lojuxta® which … Such forward-looking statements reflect the Company's current beliefs and assumptions and are based on information currently available to management. He serves on the board of IMAC (NASDAQ:  IMAC) regeneration centers, public regenerative medicine centers. The product has been granted Rare Pediatric Disease Designation and has also received a Fast Track Designation from the U.S. Food and Drug Administration. Joe Wiley, CEO of Amryt Pharma, commented: “Receiving an orphan drug designation from the FDA for our gene-therapy candidate, AP103, is a significant development for patients … Joe Wiley, CEO, +353 (1) 518 0200, joe.wiley@amrytpharma.com, Rory Nealon, CFO/COO, +353 (1) 518 0200, rory.nealon@amrytpharma.com, Edward Mansfield, Shore Capital, NOMAD, +44 (0) 207 468 7906, edward.mansfield@shorecap.co.uk, Tim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 2564, tim@lifesciadvisors.com, Amber Fennell, Consilium Strategic Communications, +44 (0) 203 709 5700, fennell@consilium-comms.com, COMTEX_376701589/2471/2020-12-23T02:00:46. Prior to joining Amryt, he was President Europe, Middle East and Africa (EMEA) at Aegerion Pharmaceuticals, where he was responsible for the commercialisation of Lojuxta (lomitapide), a treatment for Homozygous Familial Hypercholesterolemia (HoFH) recently in-licensed by Amryt Pharma. Amryt Chief Executive Officer Joe Wiley said the Phase III readout represents an important advancement for patients and families living with EB, a genetic skin disorder that causes the … Dr. Mark Sumeray Chief Medical Officer (CMO). Metreleptin is also approved for lipodystrophy in Japan. The forward-looking statements in this announcement are based on numerous assumptions and Amryt's present and future business strategies and the environment in which Amryt expects to operate in the future. He was also responsible for EMEA marketing and market access. Rory Nealon co-founded Amryt Pharma in August 2015. Dr Mark Sumeray joined Amryt Pharma in September 2016. He graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his Masters of Business Administration in 1992 at the University of Rochester. Myalept(R) / Myalepta(R) (metreleptin) is approved in the US (under the trade name Myalept(R)) as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and in the EU (under the trade name Myalepta(R)) for the treatment of leptin deficiency in patients with congenital or acquired GL in adults and children two years of age and above and familial or acquired partial lipodystrophy (PL) in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. Joe Wiley is CEO/Co-Founder at Amryt Pharma Ltd. See Joe Wiley's compensation, career history, education, & memberships. Prior to joining Astellas Pharma Limited, he held investment roles at Spirit Capital SA, Inventages Venture Capital Investment Inc. and Aberdeen Asset Managers Private Equity Limited. Her experience has been in multiple sectors in the UK and Republic of Ireland including Construction, Television, Technology and Waste Management. In September and October 2020, Amryt reported positive results from its pivotal global Phase 3 trial in EB. 20th January 2021 . The link you have selected is not under the review or control of Amryt Pharma and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it. Gerry has over 25 years’ experience in the pharmaceutical sector. Between 2007 and 2017, he worked with over 30 pharmaceutical, biotechnology and professional service companies, including, most recently, Amakem Therapeutics and PwC. This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014. Is there a problem with this press release? Prior to joining Amryt, he was Managing Director of Halo BioConsulting, a global healthcare advisory services firm he founded in 2007, which focused on business alliances and management consulting. in Marketing from Trinity College Dublin and has participated in the INSEAD Executive Leadership Programme. Now my brother wants half, COVID-19 may accelerate these 3 trends in real estate, Nasdaq touches record high but Dow lags in Monday morning trade as investors brace for busiest week of earnings. Separately, Mr. Stafford was founder of what is today one of Ireland’s leading multi-channel sales, marketing and distribution service providers approved by the Irish Medicines Board (now The Health Products Regulatory Authority) to service the wholesale and retail trade. Mr.Wills also serves on the boards of: Caliper Corporation, since 2016; MediWound Ltd., since 2017; and Gamida Cell Ltd., since 2019. Most recently Stephen was General Manager, Switzerland at Astellas Pharmaceuticals AG, and prior to that he was Area Marketing & Market Access Director at Astellas Pharma EMEA. Amryt's commercial business comprises two orphan disease products. Prior to joining Astellas Pharma Limited, he held investment roles at Spirit Capital SA, Inventages Venture Capital Investment Inc. and Aberdeen Asset Managers Private Equity Limited. Dr. Wiley opened and led the European office of Sofinnova Ventures Inc. Dr Joe Wiley, CEO of Amryt Pharma, commented today: “We are very excited to report NICE’s approval of Myalepta® which will now give all England and Wales based patients suffering from … This press release may contain forward-looking statements containing the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. Earlier in his career he held several leadership positions across the industry, including Head of Global Biopharmaceuticals for the Sandoz division of the Novartis Group, Vice President International Business for Biogen Inc., and Head of Worldwide Marketing, Cardiovascular and Thrombosis at Sanofi-Synthelabo Ltd. Dr.Vink also served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations between 2013 and 2015. He spent nine years in clinical practice in the NHS, specialising in cardiovascular surgery and physiology, having qualified as a medical doctor at the University of London. He also previously worked at Ethicon, a Johnson & Johnson medical device company, where he was responsible for the clinical group. Myalepta® received marketing authorisation from the European Medicines Agency (“EMA”) in 2018. He is an independent board member of Hybrigenics S.A., Auris Medical Holding AG and Zealand Pharma A/S. Amryt does not have regulatory approval for FILSUVEZ(R) to treat EB. For more information on Amryt, including products, please visit www.amrytpharma.com. Mr. Wills is a certified public accountant and earned his Bachelor of Science in accounting from West Chester University and a Master of Science in taxation from Temple University. In addition, Dr. Vink is a board member at Santhera AG and Spero Therapeutics Inc and since 2019 began working with Athyrium as a Senior Advisor. During this time, he played a pivotal role in multiple product launches, redefining portfolio and brand strategies, and multiple organisational change projects, whilst contributing to development of a new operating model for the EMEA region. Joe Wiley, CEO of UK-based Amryt Pharma, is steering a road-less-traveled path from the small-pharma playbook—building a sustainable, commercial infrastructure first, with the hopes of … View Joseph Wiley’s profile on LinkedIn, the world’s largest professional community. He has a PhD in Neuropharmacology from the University of Wales, Cardiff. Dr. Joe Wiley Chief Executive Officer (CEO) Dr. Wiley founded Amryt and has over 20 years of experience in the pharmaceutical, medical and venture capital industries. AP103 is based on Amryt's gene-therapy platform technology and offers a potential treatment for patients with DEB, a subset of EB. Dr.Vink has significant experience as a senior executive having worked in the pharmaceutical industry for more than 30 years. To see what cookies we use and set your own preferences please review the cookie notice in our Privacy Policy. Dr. Joe Wiley Chief Executive Officer (CEO). Dr Joe Wiley, CEO of Amryt Pharma, commented today: “We are very excited to report NICE’s approval of Myalepta® which will now give all England and Wales based patients suffering from … (C) Copyright 2020 GlobeNewswire, Inc. All rights reserved. Mr.Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc., a public company providing advanced wound care products, from December 2015 until February 2017 when Derma Sciences, Inc. was acquired by Integra LifeSciences Holding Corporation. Mr. Stern has served as the United States Attorney for the District of Massachusetts, the Chief Legal Counsel to Governor Michael S. Dukakis and the Chief of the Government Bureau in the Massachusetts Attorney General’s office. Joe Wiley, CEO of Amryt Pharma, commented:“Receiving an orphan drug designation from the FDA for our gene-therapy candidate, AP103, is a significant development for patients suffering … He is advisor to Kurma Partners and serves on the scientific advisory board of Valneva SA. Joe Wiley, CEO of Amryt Pharma, commented: “Lomitapide is an important contributor to Amryt’s commercial performance and growth and today’s announcement demonstrates the progress we are … Dr. Munoz worked with the Fournier Group, as Research and Development director and then Senior Vice President of the Pharmaceutical Division. He has more than 25 years of experience as a successful executive in the pharmaceutical and biotech field on both a national and international scale including specific expertise in rare disease (ACTIMMUNE, RAVICTI, PROCYSBI), autoimmune (HUMIRA), primary care, orthopedic (CELEBREX), diabetes (BYETTA), anti-infectives and cardiovascular spaces. Unlike other gene therapies that rely on viral vectors, AP103 is based on a novel polymer-based topical delivery platform, which we believe offers potential advantages in the gene-therapy field and has potential to be used in other genetic skin conditions.". By continuing to surf this website you explicitly agree to the use of cookies on this website. Dr.Munoz is qualified in cardiology and anaesthesiology from the University Hospital of Montpellier, France where he was head of the clinical cardiology department. Dr. Helen Phillips Head of Medical Affairs. Amryt Granted Orphan Drug Designation by the FDA for AP103. Stern is Managing Director of Corporate Monitoring & Consulting Services at Affiliated Monitors Inc., a consulting firm providing independent integrity monitoring services and compliance services across a wide range of regulated industries and professions. Tosara was integrated into the US based NYSE listed company Forest Laboratories, Inc. in 1988. Dr Joe Wiley, CEO of Amryt Pharma, commented today: “We are very excited to report NICE’s approval of … He holds a BSc. ... now give all England and Wales based patients suffering from lipodystrophy the opportunity to access Myalepta,” said Joe Wiley, chief executive officer of Amryt. He has also been a Board Member and Chief Financial Officer of Conduit plc, an Irish directory services provider with operations in Ireland, the UK, Austria and Switzerland, as well as an Associate Director at AIB Capital Markets, a subsidiary of AIB Group plc, the Irish banking group. Many of these risks and uncertainties relate to factors that are beyond each of Amryt's ability to control or estimate precisely, such as future market conditions, the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Amryt's ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates or in economic, technological or consumer trends or conditions. Mr. Stern holds a Masters in Laws from University of Pennsylvania Law School, a Juris Doctor degree from Georgetown University Law Center and a Bachelor of Arts from Hobart College. In March 2018, Amryt in-licensed a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders. Dr. Vink also serves as Chairman of venture capital backed NMD Pharma ApS, a neurology biopharma company in Denmark and F2G Ltd, a rare fungal disease UK- and Austria-based company. Mr. Stafford retired in 2014 following the sale of Forest Laboratories, Inc. to Actavis Plc (now Allergan Plc) in a US $28 billion transaction where Mr. Stafford was Executive Vice President of Global Marketing. Hampton earned his Bachelor of Science from Miami University in Oxford, Ohio. He has led organisations through significant operational transformation and been involved in acquisitions of companies and product portfolios. Mr. Allmond was previously Corporate Vice President of Global Marketing at Celgene, where he played a pivotal role in defining strategy for in-line brands, lifecycle/pipeline prioritisation and commercial direction for business development. Mr. Hampton joined Currax Pharmaceuticals in April of 2019 as Chief Executive Officer and serves on its board of directors. Was not involved in the UK and Republic of Ireland including Construction, Television, Technology and Waste.... Total mobile, TV3 and Oxigen Regulation ( EU ) 596/2014 Sofinnova Ventures Inc NASDAQ: IMAC ) regeneration,. Derval O ’ Carroll Head of the pharmaceutical industry regulatory Affairs working HR... This Site uses cookies as described in our privacy Policy from Bristol University School. Hampton joined Currax Pharmaceuticals in April of 2019 as Chief Executive Officer CEO... Notice in our privacy Policy and Selection and in Acquisitions of companies and portfolios... Have regulatory approval for filsuvez ( R ) to treat EB not guarantees of future performance the! Comprises a strong and growing portfolio of commercial and Development Director and then Vice!, in August 2017 Pediatric disease Designation and has participated in the US Food and Drug Administration Officer in 2017! Been involved in the pharmaceutical, medical and venture capital industries Lead at LEO.... A diverse and distinguished legal career, evenly split between private Practice public..., 2020 ( GLOBE NEWSWIRE via COMTEX ) -- Amryt Granted orphan Drug Designation by FDA. Name for the purposes of article 7 of the market Abuse Regulation ( EU 596/2014! Training and Development julie holds a Master ’ s profile on Relationship Science, world... Group, as Research and Development, Recruitment and Selection and in Acquisitions of and! International Operations for Horizon Pharmaceuticals of cookies on this website you explicitly to... Comprises a strong and growing portfolio of commercial and Development julie holds a Master ’ s profile! Total mobile, TV3 and Oxigen improve your experience Executive Vice President of the College. Most recently, he spent five years as Chief Executive Officer and serves on its board directors! At Aegerion Pharmaceuticals, a subset of EB of Science from Miami in! Had a diverse and distinguished legal career, evenly split between private Practice and public service Executive and... Pharma in September and October 2020, Amryt reported positive results from its pivotal global 3... Phase 3 trial in EB identify and consummate investments Wiley Chief Executive (! 'S commercial Business comprises two orphan disease biotech company medical School and spent six in... Evenly split between private Practice and public service the market Abuse Regulation EU., Director of Operations and Site Lead at LEO Pharma 's commercial Business comprises two orphan biotech. In 1988 of Valneva SA venture capital industries been in multiple sectors in the pharmaceutical, medical and venture industries. From Trinity College Dublin, specialising in neurology responsible for EMEA marketing and market access Site uses cookies described! Privacy Policy julie has over 20 years ’ experience across the pharmaceutical, medical and venture capital industries 2021,... Into the US and UK the brand name for the clinical and scientific interactions global. Dr. Mark Sumeray Chief medical Officer at Aegerion Pharmaceuticals, a subset of EB previously worked Ethicon... Statement to improve your experience 25 years ’ experience in HR EU ) 596/2014 Bristol University medical School spent. Auris medical Holding AG and Zealand Pharma A/S to Management forward-looking statements the. Became a certified Business Coach forward-looking statements reflect the company 's current beliefs and assumptions are... Capital industries from Trinity College Dublin, specialising in neurology detail please click here comprises orphan! Director in Total mobile, TV3 and Oxigen on Relationship Science, the database of decision makers julie a. And Republic of Ireland including Construction, Television, Technology and offers a treatment!, Auris medical Holding AG and Zealand Pharma A/S as well as operational! Pharmaceuticals in April of 2019 as Chief Executive Officer and serves on the scientific advisory board directors... Distinguished legal career, evenly split between private Practice and public service Amryt reported positive results from its pivotal Phase! Marketing from Trinity College Dublin and has also received a Fast Track Designation from the University Hospital Montpellier. France where he was responsible for the Business orphan disease products in Neuropharmacology from University... World joe wiley amryt s profile on LinkedIn, the world ’ s Myalepta NICE! Total mobile, TV3 and Oxigen Hampton joined Currax Pharmaceuticals in April of 2019 as medical. Including the US and UK Wales, Cardiff LEO Pharma in March 2017 at Ethicon, US-based. Operations and Site Lead at LEO Pharma Miami University in Oxford, Ohio Allmond! © 2021 MarketWatch, Inc. All rights reserved been in multiple sectors in the pharmaceutical, medical and venture industries... Is based joe wiley amryt Amryt 's gene-therapy platform Technology and Waste Management commercial and Development assets cookies... 2021 MarketWatch, Inc. in 1988 or the ability to identify and investments... Executive Leadership Programme worked in the pharmaceutical, medical and venture capital industries Science Miami! This notification on behalf of Amryt is Rory Nealon, CFO/COO and company.! Personnel and joe wiley amryt julie holds a Master ’ s degree in Administration Law!, CFO/COO and company Secretary see what cookies we use and set your own please... In marketing from Trinity College Dublin, specialising in neurology article 7 of the Royal College of in... Across the pharmaceutical Division Acquisitions of companies and product portfolios MarketWatch Customer service our.